Yellow fever vaccine is highly effective with a single dose, but vaccine supply is limited. The minimum dose requirements for seroconversion remain unknown. In this double-blind, randomized ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when ...

Dr. Brian Y. Chang (Medicine): A 62-year-old man was admitted to this hospital because of abdominal pain. Two years before the current presentation, postprandial abdominal pain developed.

Two years of empagliflozin treatment in patients with chronic kidney disease slowed progression and reduced cardiovascular risk. Findings from a 2-year post-trial follow-up are summarized in a ...

The WHO advises using fractional doses of the 17D yellow fever vaccine when outbreaks occur during vaccine shortages, but evidence on the immunogenicity of these lower doses is limited. New ...

Food and nutrition security exists when all people at all times have access to nutritious food for the prevention and treatment of disease and the promotion of health and well-being. Food and ...

Many inhalers that are vital for patients with asthma or COPD are associated with societal harms that can worsen the very diseases the products are designed to treat. How can this dilemma be resolved?

Use of antiarrhythmic drugs or catheter ablation to suppress recurrent ventricular tachycardia is often warranted, but studies comparing the two approaches are limited. New research findings from ...

How combination therapy with acalabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, compares with chemoimmunotherapy in patients with previously untreated CLL has been unclear.

Supported by Swim Across America, the Simon and Eve Colin Foundation, the Dalton Family Foundation, the American Association for Cancer Research–Stand Up To Cancer Colorectal Cancer Dream Team ...

In patients with acute myocardial infarction, treatment with the antiinflammatory agent colchicine may improve cardiovascular outcomes; however, results of clinical trials are mixed. New research ...